Amplitude Titration to Improve ECT Clinical Outcomes
Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial
University of New Mexico
50 participants
Sep 14, 2023
INTERVENTIONAL
Conditions
Summary
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency
Eligibility
Inclusion Criteria2
- Diagnosis of major depressive disorder or bipolar II
- Clinical indications for ECT with right unilateral electrode placement
Exclusion Criteria4
- Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
- Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)
- Current drug or alcohol use disorder (except for nicotine)
- Contraindications to MRI.
Interventions
Device permits individualized amplitudes
FDA approved ECT device with fixed amplitude.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05699226